Clinical Observation of Fuzheng Jiedu Prescription Combined with Sindilizumab+Nab-PP Regimen in Treatment of Patients with Advanced Non-small Cell Lung Cancer
Objective:To observe the efficacy and safety of Fuzheng Jiedu prescription combined with neotilizumab+Nab-PP regimen in the treatment of advanced cancer.Methods:40 patients with advanced cancer admitted to Xu-zhou Traditional Chinese Medicine Hospital from January 2022 to May 2023 were selected.The patients were divided into control group and treatment group by random grouping method,with 20 cases in each group.The control group was treated with the sintilimab+Nab-PP regimen alone,and the treatment group was treated with the sintilimab+Nab PP regimen combined with Fuzhengjiedu.The disease control rate,tumor marker indicators before and after treatment,changes in TCM syndrome scores and adverse reactions of the two groups of patients after 4 courses of treatment were observed.Results:The disease control rate in the treatment group was 80.0%,and that in the control group was 70.0%.The difference was not statistically significant(P>0.05).The levels of CYFRA21-1,CA125 and CEA in the treatment group were lower than before treatment,which was statistically significant(P<0.05),compared with the control group,the decrease was more significant and statistically significant(P<0.05).The decrease in CA125 was not statistically significant(P>0.05).Comparing the TCM syndrome scores,the scores of the treatment group were lower than those of the control group,and the difference was statistically significant(P<0.05).There were statistically significant differ-ences in adverse reactions such as vomiting,diarrhea,and loss of appetite(P<0.05).However,in terms of rash,thyroid dysfunction,and bone marrow suppression,it was better than the control group in terms of rash,thyroid dysfunction,and bone marrow suppression,but there was no statistical significance(P>0.05).Conclusion:Fuzheng Jiedu Recipe can effectively improve the quality of life of patients with advanced non-small cell lung cancer,improve the efficacy of sin-tilimab+Nab-PP regimen,and reduce adverse reactions.
国家科技期刊平台
NSTL
万方数据
